multi-antigen-directed autologous T cells NEXI-002
A preparation of autologous T cells targeting several multiple myeloma (MM)-associated antigens, with potential immunomodulating and antineoplastic activities. Peripheral blood mononuclear cells (PBMC) from the patient are collected and ex vivo exposed to nanoparticles that mimic antigen-presenting cells (APCs) loaded with multiple MM-associated antigens, including Wilms' tumor 1 (WT1), CD138 (syndecan-1; SDC1), cancer-testis antigen NY-ESO-1 and CS1 (CD319; CRACC; SLAMF7), and are further enriched and expanded ex-vivo before being re-introduced into the patient. Upon administration, the multi-antigen-directed autologous T cells NEXI-002 are re-introduced into the patient, where they target and kill tumor cells expressing these antigens.
| Synonym: | autologous MM-associated antigens specific T cells NEXI-002 NEXI-002 T cells TAA primed antigen-specific CD8+ T cells NEXI-002 |
|---|---|
| Code name: | NEXI 002 NEXI002 |